In the trial, severe adverse events occurred in 54% patients in the sunitinib group versus 49% in the placebo group, the most frequent being asthaenia/fatigue (18% versus 3%) and hypertension (10% ...

In this randomized, double-blind, phase 3 trial, we assigned 615 patients with locoregional, high-risk clear-cell renal-cell carcinoma to receive either sunitinib (50 mg per day) or placebo on a 4 ...

We analyzed serum cobalamin, holotranscobalamin, folate, and homocysteine levels 5 to 10 months after the initiation of sunitinib treatment; however, we did not perform such an analysis at baseline.

Sunitinib (Pfizer, New York, NY) is an oral, multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor receptors and other receptor tyrosine kinases. 9–15 Sunitinib has shown ...

The median progression-free survival was 8.4 months with pazopanib and 9.5 months with sunitinib (hazard ratio, 1.05; 95% confidence interval, 0.9–1.22). Median survival was 28.4 months with ...

A 24-patient, single-arm trial studying second-line sunitinib 50 mg daily for 4 weeks on and 2 weeks off in SCLC reported a 9% PR and 29% SD rate with significant toxicity (63% grade 3 or 4 ...

There was an increased risk of cardiovascular events associated with sunitinib or sorafenib use (hazard ratio [HR], 1.38), especially for stroke (HR, 2.84), compared with the 788 patients ...

Leukemia - Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D3 ...

An exploratory retrospective analysis of data from six key trials in patients with metastatic renal cell carcinoma (mRCC) has revealed that sunitinib has comparable efficacy regardless of patient ...

Sunitinib was approved for use in RCC in 2006, and global sales were $1.19 billion in 2011. Pazopanib was approved for RCC in 2009, and sales were $160 million in 2011.

Sunitinib is a small molecule tyrosine kinase inhibitor that targets multiple receptors, including VEGFR2, c-Kit and FLT3. These receptors may be present in cancer cells as well as in endothelial ...

Researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma, a deadly form of kidney cancer.